Introduction {#s1}
============

The central nervous system comprises an elaborate network of neuronal populations that have been identified to control energy homeostasis ([@bib51]; [@bib57]). This extensive network includes neural circuits that operate within ([@bib6]; [@bib9]; [@bib38]; [@bib42]; [@bib45]; [@bib48]; [@bib72]; [@bib77]) and beyond ([@bib27]; [@bib33]; [@bib79]) the hypothalamus. Of these, the arcuate nucleus of the hypothalamus (ARC) is most actively studied. The key components of the feeding circuit in ARC have been identified to comprise agouti-related protein/neuropeptide Y (AgRP/NPY)-expressing neurons and pro-opiomelanocortin (POMC)-expressing neurons ([@bib6]; [@bib9]; [@bib45]; [@bib79]), although an earlier study ([@bib44]) suggests other cell types may function as additional regulators. In particular, little is known about the functional role of glial fibrillary acidic protein (GFAP)-expressing glia that co-exist in the same brain circuit as these neurons.

Glia represent a major cell population in the brain, with their numbers at least equaling those of neurons. Traditionally viewed as passive support elements, recent research has unraveled their important roles in the modulation of multiple physiological functions ([@bib15]; [@bib28]; [@bib30]; [@bib53]; [@bib66]). GFAP-expressing hypothalamic glia, particularly astrocytes, have extensive structural connections with neurons ([@bib34]) and also express the receptor for the satiety hormone, leptin ([@bib17]; [@bib35], [@bib36]; [@bib37]; [@bib41]; [@bib56]) and for insulin ([@bib25]). Another type of GFAP-expressing hypothalamic glia, tanycytes, are interestingly glucosensitive and are activated by transmitters related to arousal and feeding ([@bib12]; [@bib19]; [@bib64]). These findings suggest a potential role of glia in the regulation of energy homeostasis, thereby opening up several key questions: Do GFAP-expressing hypothalamic glia play a role in the regulation of feeding? Do they functionally interact with AgRP/NPY and/or POMC neurons? If so, how does manipulation of glia in ARC affect food intake and feeding behavior? Here we demonstrate that direct and acute glial activation in the mouse ARC facilitates the activity of AgRP/NPY but not POMC neurons and is sufficient to reversibly evoke feeding. In the presence of AgRP/NPY neuronal inactivation, acute ARC glial activation did not evoke any change in feeding. In addition, disruption of Ca^2+^ signaling in ARC glia leads to reduced food intake. This reveals an important role of ARC glia-AgRP/NPY neuron circuit in the regulation of energy homeostasis.

Results {#s2}
=======

Selective expression and activation of DREADDs in ARC glia {#s2-1}
----------------------------------------------------------

To acutely activate glia *in vivo*, we selectively expressed designer receptors exclusively activated by designer drugs (DREADDs) ([@bib4]; [@bib8]) in GFAP-expressing glia in ARC of C57BL/6 adult mice. This was achieved by stereotaxic injection in ARC with an adeno-associated virus (AAV) containing a *Gfap* promoter-driven gene that encodes the evolved human M3-muscarinic receptor fused to mCherry (hM3D(Gq)-mCherry) ([Figure 1A](#fig1){ref-type="fig"}). The hM3D(Gq) couples to the Gq protein-mediated signaling to activate glia upon binding of clozapine-N-oxide (CNO). CNO is an exclusively specific ligand of DREADD ([@bib1]) and is inert when used at low concentrations (see CNO dose experiments in [Figure 2---figure supplement 1B--D](#fig2s1){ref-type="fig"}). Successful bilateral viral injection in ARC was confirmed by localized expression of mCherry ([Figure 1B](#fig1){ref-type="fig"}). The hM3D(Gq)-mCherry was selectively expressed in glia and not in neurons. This was evidenced by the co-localization of mCherry with anti-GFAP ([Figure 1C](#fig1){ref-type="fig"}) and anti-S100B ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}: 93.9% of mCherry-expressing cells (*n* = 401/430 cells in 12 animals) were immunopositive for S100B) but not with anti-neuronal nuclei (NeuN) immunohistochemistry stains ([Figure 1D](#fig1){ref-type="fig"}). There was also no expression of mCherry in specific neuronal sub-types: orexigenic AgRP/NPY neurons and anorexigenic POMC neurons in *Npy*-hrGFP and *Pomc*-EGFP mice respectively ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}: 99.1% of GFP-expressing neurons in *Npy*-hrGFP mice (*n* = 733/744 neurons in 11 animals) and 99.3% of GFP-expressing neurons in *Pomc*-EGFP mice (*n* = 439/448 neurons in 9 animals) did not express mCherry). The hM3D(Gq)-mCherry glial population comprised both astrocytes and tanycytes that line the third ventricle ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}: 14.9% of the mCherry-expressing cells co-localized with anti-vimentin, a marker for tanycytes (*n* = 80/512 mCherry-expressing cells in 4 animals). *In vivo* injections of CNO (0.3 mg/kg) ([@bib43]; [@bib45], [@bib46]; [@bib60]) induced significantly greater Fos immunoreactivity ([@bib55]; [@bib62]) as compared to saline injections in ARC astrocytes ([Figure 1E--F](#fig1){ref-type="fig"}: *n* = 95 mCherry-expressing astrocytes in 5 animals each for saline and CNO groups, p=0.0114, unpaired *t*-test, comparing averaged responses across astrocytes in each saline- and CNO-injected animal) but not in tanycytes ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). CNO, but not saline application in ARC slices ([Figure 1G](#fig1){ref-type="fig"}) also evoked robust Ca^2+^ responses in hM3D(Gq)-mCherry-expressing astrocytes ([Figure 1H--I](#fig1){ref-type="fig"}: *n* = 42 mCherry-expressing astrocytes in 3 animals each for saline and CNO groups, p=5.49E-16, unpaired *t*-test, comparing averaged responses across astrocytes in the saline- and CNO-injected animals). A greater complexity of astrocytic processes was also observed in CNO-injected animals as compared to saline-injected animals ([Figure 1---figure supplement 1D--F](#fig1s1){ref-type="fig"}).10.7554/eLife.18716.003Figure 1.CNO-dependent activation of hM3D(Gq)-mCherry expressing ARC glia evokes increased Fos immunoreactivity and elevated intracellular Ca^2+^.(**A**) Design of the AAV construct expressing hM3D(Gq)-mCherry under the *Gfap* promoter. (**B**) (**Left**) Schematic drawing showing the location of ARC (red) in a coronal brain slice (**Right**) An example DAPI-stained (blue) coronal brain slice containing hM3D(Gq)-mCherry (red) expressing glia in ARC. Scale bar, 1 mm. (**C**--**D**) DAPI, anti-GFAP and anti-NeuN immunohistochemistry showing expression of hM3D(Gq)-mCherry in glia but not in neurons. (**Inset**) Magnified image of a hM3D(Gq)-mCherry expressing glial cell and non hM3D(Gq)-mCherry expressing neurons. Scale bars, 10 µm. (**E**) *In vivo* injection of CNO but not saline induces Fos immunoreactivity in hM3D(Gq)-mCherry-expressing (red), S100B-positive (green) ARC astrocytes. Animals were perfused for Fos quantification 2 hr post injection. Scale bar, 10 µm. (**F**) Population mean of normalized Fos expression in astrocytes following saline or CNO injection. (**G**) Configuration of calcium imaging of OGB-1-AM loaded, hM3D(Gq)-mCherry expressing astrocytes in ARC coronal slices during CNO application. (**H**) Local application of CNO but not saline (red dot; 10 mM, 20 psi, 200 ms) evoked a robust Ca^2+^ increase in ARC astrocytes. (**I**) The population average of mean% fluorescence change (dFF) of astrocytes when CNO or saline was applied. \*p\<0.05, \*\*\*\*p\<0.0001. Error bars represent SEM. See also [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.003](10.7554/eLife.18716.003)10.7554/eLife.18716.004Figure 1---figure supplement 1.DREADDs are specifically expressed in glial cells. Astrocytes, but not tanycytes, are activated by DREADDs and fasting. Morphological changes in astrocytes are also induced by DREADDs and fasting. (**A**) Expression of hM3D(Gq)-mCherry (red) (Left) co-localizes with anti-S100B (green) immunohistochemistry but did not co-localize with (Middle) GFP (green) in *Npy*-hrGFP and (Right) *Pomc*-EGFP slices. Scale bars, 20 µm. (**B**) Anti-vimentin immunohistochemistry showing expression of hM3D(Gq)-mCherry in some of the vimentin-expressing tanycytes lining the third ventricle (3V). Scale bars, 50 µm (left), 10 µm (right). (**C**) Population mean of normalized Fos expression in hM3D(Gq)-mCherry-expressing tanycytes 2 hr after saline or CNO (0.3 mg/kg) injection. *n* = 51 mCherry-expressing tanycytes in 6 saline-injected animals, *n* = 25 mCherry-expressing tanycytes in 4 CNO-injected animals, p=0.364, unpaired *t*-test, comparing averaged responses across tanycytes in each saline- and CNO-injected animal (**D**) anti-GFAP immunohistochemistry (green) revealing the morphology of hM3D(Gq)-mCherry (red) expressing ARC astrocytes 2 hr after *in vivo* injection of (Left) saline and (Right) CNO (0.3 mg/kg). Scale bars, 10 µm. (**E**) Sholl analysis of length and (**F**) intersections made by processes of hM3D(Gq)-mCherry ARC astrocytes revealed greater complexity in astrocytic morphology after *in vivo* injection of CNO compared to that of saline. n = 15 mCherry-expressing astrocytes in 5 animals in each group. (**G**) Fasting induces greater Fos immunoreactivity in S100B-positive ARC astrocytes and S100B-negative putative ARC neurons (but not in tanycytes) as compared to fed animals. Population mean of normalized Fos expression in ARC astrocytes, neurons and tanycytes of fasted and fed animals is shown. Fed: *n* = 440 astrocytes, 442 neurons and 244 tanycytes in 11 animals, Fasted: *n* = 400 astrocytes, 402 neurons and 226 tanycytes in 10 animals, p=0.0393/ p=0.0164/ p=0.279, unpaired *t*-test, comparing averaged responses of astrocytes/neurons/tanycytes between the fasted and fed animals. (**H**) anti-GFAP immunohistochemistry revealing the morphology of ARC astrocytes in (*Left*) fed and (Right) fasted animals. Scale bars, 10 µm. (**I**) Sholl analysis of length and (**J**) intersections made by the processes of ARC astrocytes revealed greater complexity in astrocytic morphology in fasted as compared to fed animals. n = 18 astrocytes in 6 animals in each group. In [Figure 1---figure supplement 1G--J](#fig1s1){ref-type="fig"}, fasted and fed animals were perfused 16--18 hr post initiation of fasting in fasted animals. Fed animals were given *ad libitum* access to food. In [Figure 1---figure supplement 1E--F,1I--J](#fig1s1){ref-type="fig"}, two-way ANOVA followed by Bonferroni post hoc tests was used. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001. N.S., not significant. Error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.004](10.7554/eLife.18716.004)

Notably, the physiological activation of ARC during fasting also induced Fos immunoreactivity in ARC astrocytes and neurons but not in tanycytes ([Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}). A greater complexity of astrocytic processes was also observed in fasted animals as compared to fed animals ([Figure 1---figure supplement 1H--J](#fig1s1){ref-type="fig"}). These data suggest that activation of hM3D(Gq)-mCherry in astrocytes can induce both the functional and morphological changes observed during physiological activation of astrocytes after fasting. Collectively, these results confirm the specific and selective expression and activation of hM3D(Gq)-mCherry in ARC glia (mainly astrocytes), thereby allowing investigation of the functional effects of physiological activation of ARC glia.

Acute activation of ARC glia reversibly induces increased food intake {#s2-2}
---------------------------------------------------------------------

To assess the effect of ARC glial activation on feeding, we compared the food intake of viral-injected, *ad libitum* fed mice in custom-designed cages ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}) on days with CNO injection to that under control conditions. The control conditions included (1) cage acclimatization without injection (baseline), (2) with saline injection before CNO injection (pre-CNO saline) and (3) after CNO injection (post-CNO saline). The comparison of food intake following saline and CNO injections allowed the same animal to be used as its own control ([Figure 2A](#fig2){ref-type="fig"}), since CNO, but not saline, can activate hM3D(Gq)-mCherry-expressing glia specifically ([Figure 1E--I](#fig1){ref-type="fig"}) ([@bib1]). The CNO dose was selected to be 0.3 mg/kg ([@bib43]; [@bib45], [@bib46]; [@bib60]) for all experiments, as concentration experiments in control mice with low (0.3 mg/kg) and high (5 mg/kg) ([@bib78]) CNO concentrations revealed non-specific inhibition of food intake at high but not low CNO concentration ([Figure 2---figure supplement 1B--D](#fig2s1){ref-type="fig"}). Saline or CNO injections were performed at 09:00, 2 hr after the start of light phase when mice were in a calorically replete state. Feeding measurements were made between 09:00--17:00. Interestingly, the average total food intake during days of CNO administration was about three- to four-fold greater than that during baseline, pre-CNO saline and post-CNO saline ([Figure 2B](#fig2){ref-type="fig"}: p\<0.0001, *n* = 11 animals, unpaired *t*-test comparing total food intake during three days of CNO with that during three days of baseline, three days of pre-CNO saline and four days of post-CNO saline). This feeding response was reversible and reproducible across repeated CNO administration in the same animal ([Figure 2B](#fig2){ref-type="fig"}), suggesting that glial activation may serve as an intrinsic regulatory mechanism of food intake.10.7554/eLife.18716.005Figure 2.CNO-dependent activation of hM3D(Gq)-mCherry expressing ARC glia evokes increased day food intake, time spent at food chamber and food seeking attempts in C57BL/6 mice.(**A**) Schematic of experimental paradigm. The mice were allowed to recover and for hM3D(Gq)-mCherry to be expressed 2--3 weeks post viral injection before acclimatization in custom cages for 3--7 days (baseline) and to saline injection for three days (pre-CNO saline). CNO injections were repeated for three days, each separated by two days of saline injection (post-CNO saline) to allow the CNO effects to clear. All injections were performed at 09:00 while the food intake was measured at specific time points between 09:00--17:00. All mice were housed in custom cages between 09:00--17:00 and returned to the standard cages after 17:00 daily. (**B**) Total food intake between 09:00--17:00 during baseline, pre-CNO saline, CNO and post-CNO saline averaged across animals. Dotted line 1 refers to the averaged total food intake across baseline, pre- and post- CNO saline while dotted line 2 refers to two folds of this average. (**C**) Food intake during hourly time points from 09:00 to 17:00 (except from 09:00--09:30 and 09:30--10:00 where 30 min time points were used) during pre-CNO saline and CNO administration. (**D**) The percentage of time mice spent at food chamber relative to other cage areas during specific time points following pre-CNO saline and CNO administration. (**E**) The frequency of attempts made to access the food chamber during specific time points following pre-CNO saline and CNO administration. In [Figure 2C--E](#fig2){ref-type="fig"}, values between 09:00--09:30 and 09:30--10:00 were normalized to hourly values. Pre-CNO saline and CNO values were averaged across three days of repeats before computing the average across animals. Two-way ANOVA followed by Bonferroni post hoc tests was used. \*p\<0.05, \*\*p\<0.01, \*\*\*\*p\<0.0001. Error bars represent SEM. See also [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"}--[6](#fig2s6){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.005](10.7554/eLife.18716.005)10.7554/eLife.18716.006Figure 2---figure supplement 1.CNO administered at 5 mg/kg (but not at 0.3 mg/kg) induces non-specific effects on feeding in animals without DREADD expression. CNO(0.3 mg/kg) evoked robust feeding behavior in animals with hM3D(Gq)-mCherry-expressing ARC glia. (**A**) Setup of custom-designed, open-top cages comprising a food chamber, a drinking spout/water bottle, mouse igloo and sterile gauzes. The mouse igloo was positioned opposite to the food chamber in each cage to serve as an alternative location for rest and play while the animal was not feeding at the food chamber. The bedding was removed and replaced with sterile gauzes to prevent contamination of food in the chamber and therefore ensure accurate measurement of food intake. Video monitoring of the food behavior was enabled with web-cameras positioned above the cages and connected to a laptop for data storage. (**B**--**D**) Administration of CNO at 5 mg/kg but not 0.3 mg/kg induces non-specific decrease in feeding in C57BL/6 animals without hM3D(Gq)-mCherry expression. (**B**) Schematic of experimental paradigm. Mice were acclimatized to custom cages before saline injections were performed for four days. CNO injections were repeated for two days, separated by one day of saline injection to allow the CNO effects to clear. All injections were performed at 19:00 while the food intake was measured at specific time points between 19:00--23:00. All mice were housed in custom cages between 19:00--23:00 and returned to the standard cages after 23:00 daily. Cumulative food intake in C57BL/6 animals was assessed from 19:00--23:00 at the specific time points, averaged across five days of saline and two days of CNO before taking the average across animals. (**C**) Animals were injected with CNO at lower dose (0.3 mg/kg). n = 8 animals, ANOVA, Drug: p\>0.5, F (1, 7) = 0.4824; Time: p\<0.0001, F (4, 28) = 30.17; Interaction between drug and time: p\<0.02, F (4, 28) = 3.481, comparing the population and trial averaged cumulative food intake at specific time points between 19:00--23:00 during saline and CNO administration. (**D**) Animals were injected with CNO at higher dose (5 mg/kg). n = 7 animals, ANOVA, Drug: p\<0.03, F (1, 6) = 8.59; Time: p\<0.0001, F (4, 24) = 80.2; Interaction between drug and time: p=0.0005, F (4, 24) = 7.41, comparing the population and trial averaged cumulative food intake at specific time points between 19:00--23:00 during saline and CNO administration. (**E**--**F**) CNO administration (0.3 mg/kg), when compared to saline administration, induces an increase in food intake, frequency of shorter-duration feeding attempts and maximum duration of feeding episodes in animals with hM3D(Gq)-mCherry-expressing ARC glia. (**E**) Cumulative food intake from 09:00 to17:00 at the specific time points, averaged across three days of pre-CNO saline and three days of CNO administration before taking the average across animals. *n* = 11 animals, ANOVA, Drug: p\<0.0001, F~(2,24)~ = 19.5; Time: p\<0.0001, F~(8,192)~ = 39.2; Interaction between drug and time: p\<0.0001, F~(16,192)~ = 21.5, comparing the population and trial averaged cumulative food intake at specific time points between 09:00--17:00 during pre-CNO saline and CNO administration. (**F**) Frequency histograms of the food-seeking attempts of all animals during pre-CNO saline and CNO administration binned by the duration spent at the food chamber. Following CNO administration, the mode duration of food-seeking events was shorter while the skew of the distribution of duration of attempts tended towards more positive duration values than that following saline administration (p\<0.0001, Kolmogorov-Smirnov test, comparing the distribution of durations following saline and CNO administration). In [Figure 2---figure supplement 1C--E](#fig2s1){ref-type="fig"}, two-way ANOVA followed by Bonferroni post hoc tests was used. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001. N.S., not significant. Error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.006](10.7554/eLife.18716.006)10.7554/eLife.18716.007Figure 2---figure supplement 2.Activation of ARC glia evokes increased food intake within 3 hr after CNO application (0.3 mg/kg) but does not increase total food intake in the dark phase.(**A**) Schematic of experimental paradigm. Mice were acclimatized to custom cages before saline injections were performed for three days. CNO injections were repeated for three days, separated by two days of saline injection to allow the CNO effects to clear. All injections were performed at 22:00 while the food intake was measured at specific time points between 22:00--06:00. All mice were housed in custom cages between 22:00--06:00 and returned to the standard cages after 06:00 daily. (**B**) Cumulative food intake from (**Left**) 22:00--01:00, (**Middle**) 02:00--06:00 and (**Right**) 22:00--06:00 at the specific time points, averaged across seven days of saline and three days of CNO before taking the average across animals. *n* = 6 animals, ANOVA, 22:00--01:00/02:00--06:00/22:00--06:00 - Drug: p=0.0099/0.5852/0.339, F~(1,10)~ = 10.07/ F~(1,10)~ = 0.318/ F~(1,10)~ = 1.01; Time: p\<0.0001/ *p*\<0.0001/p\<0.0001, F~(3,30)~ = 195.4/F~(4,40)~ = 180/ F~(8,80)~ = 239; Interaction between drug and time: p=0.0036/0.341/0.739, F~(3,30)~ = 5.60/ F~(4,40)~ = 1.16/ F~(8,80)~ = 0.643, comparing the population and trial averaged cumulative food intake at specific time points during saline and CNO administration. (**C**) Food intake at specific time points from (**Left**) 22:00--01:00, (**Middle**) 02:00--06:00 and (**Right**) 22:00--06:00, averaged across seven days of saline and three days of CNO administration before taking the average across animals. *n* = 6 animals, ANOVA, 22:00--01:00/02:00--06:00/22:00--06:00 - Drug: p=0.0228/0.150/0.717, F~(1,10)~ = 7.22/ F~(1,10)~ = 2.43/ F~(1,10)~ = 0.139; Time: p\<0.0001/ p\<0.0001/ p\<0.0001, F~(3,30)~ = 38.2/ F~(4,40)~ = 8.21/ F~(8,80)~ = 17.2; Interaction between drug and time: p=0.0266/0.862/0.0007, F~(3,30)~ = 3.53/ F~(4,40)~ = 0.322/ F~(8,80)~ = 3.85, comparing the population and trial averaged food intake at specific time points during saline and CNO administration. Food intake during 22:00--22:30 and 22:30--23:00 were normalized to hourly values. (**D**) Total food intake between 22:00--06:00 during pre-CNO saline, CNO and post-CNO saline averaged across animals. p\>0.3, n = 6 animals, unpaired *t*-test comparing total food intake during three days of CNO administration with that during three days of pre-CNO saline and four days of post-CNO saline administration. In [Figure 2---figure supplement 2B--C](#fig2s2){ref-type="fig"}, two-way ANOVA followed by Bonferroni post hoc tests was used. \*p\<0.05, \*\*p\<0.05, N.S., not significant. Error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.007](10.7554/eLife.18716.007)10.7554/eLife.18716.008Figure 2---figure supplement 3.Analysis of viral expression showed that mCherry is specifically expressed within the ARC, although there were a few cases where the expression spread into adjacent areas in the hypothalamus.(**A**--**B**) A trend where CNO induced greater increase in food intake with increased size of viral expression within the ARC was observed. CNO-induced increase in food intake was computed by taking the averaged total food intake across days with CNO administration subtracted by that across days with saline administration. The size of viral expression is quantified by the spread of viral expression along the (**A**) caudal-rostral axis and (**B**) medial-lateral axis of ARC.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.008](10.7554/eLife.18716.008)10.7554/eLife.18716.009Figure 2---figure supplement 4.Administration of CNO (0.3 mg/kg) in mice lacking hM3D(Gq)-mCherry in GFAP-expressing ARC glia does not evoke increased food intake, frequency of feeding attempts and duration of feeding.Viral injection of AAV-*Gfap*-hM3D(Gq)-mCherry was attempted in these animals but failed. All experimental procedures were identical in mice with and without successful viral injection. (**A**) Example DAPI-stained (blue) coronal brain slice where ARC glia did not express hM3D(Gq)-mCherry. (**B**) Schematic of experimental paradigm. The mice were allowed to recover after surgery before being acclimatized to custom cages for 3--7 days (baseline) and to saline injection for three days (pre-CNO saline). CNO injections were repeated for three days, each separated by two days of saline injection (post-CNO saline) to allow the CNO effects to clear. All injections were performed at 09:00 while the food intake was measured at specific time points between 09:00--17:00. All mice were housed in custom cages between 09:00--17:00 and returned to the standard cages after 17:00 daily. (**C**) Total food intake between 09:00--17:00 during baseline, pre-CNO saline, CNO and post-CNO saline averaged across animals. p\>0.1, *n* = 8 animals, unpaired *t*-test comparing total food intake during three days of CNO administration with that during three days of baseline, three days of pre-CNO saline and 4 days of post-CNO saline administration. (**D**) Food intake during hourly time points (except from 09:00--09:30 and 09:30--10:00 where 30 min time points were used) averaged across three days of pre-CNO saline and three days of CNO administration before taking the average across animals. *n* = 8 animals, ANOVA, Drug: p\>0.4, F~(2,21)~ = 0.725; Time: p\>0.3, F~(8,168)~ = 1.16; Interaction between drug and time: p\>0.1, F~(16,168)~ = 1.33, comparing the population and trial averaged food intake at specific time points between 09:00--17:00 during pre-CNO saline and CNO administration. Food intake during 09:00--09:30 and 09:30--10:00 were normalized to hourly values. (**E**) Cumulative food intake from 09:00 to 17:00 at the specific time points, averaged across three days of pre-CNO saline and three days of CNO before taking the average across animals. n = 8 animals, ANOVA, Drug: p\>0.3, F~(2,21)~ = 1.08; Time: p\<0.0001, F~(8,168)~ = 17.8; Interaction between drug and time: p\>0.2, F~(16,168)~ = 1.29, comparing the population and trial averaged cumulative food intake at specific time points between 09:00--17:00 during pre-CNO saline and CNO administration. (**F**) The percentage of time mice spent at food chamber relative to other cage areas during specific time points averaged across three days of pre-CNO saline or three days of CNO before taking the average across animals. n = 8 animals, ANOVA, Drug: p\>0.3, F~(1,14)~ = 1.03; Time: p\<0.0001, F~(8,112)~ = 11.0; Interaction between drug and time: p\>0.4, F~(8,112)~ = 0.971, comparing the population and trial averaged percentage of time spent at specific time points between 09:00--17:00 during pre-CNO saline and CNO administration. (**G**) The frequency of attempts made to access the food chamber during specific time points averaged across three days of pre-CNO saline or three days of CNO before computing the average across animals. Values between 09:00--09:30 and 09:30--10:00 were normalized to hourly values. n = 8 animals, ANOVA, Drug: p\>0.9, F~(1,14)~ = 0.00391; Time: p\<0.0001, F~(8,112)~ = 20.6; Interaction between drug and time: p\>0.9, F~(8,112)~ = 0.203, comparing the population and trial averaged frequency of attempts at specific time points between 09:00--17:00 during pre-CNO saline and CNO administration. In [Figure 2---figure supplement 4D--G](#fig2s4){ref-type="fig"}, two-way ANOVA followed by Bonferroni post hoc tests was used. (**H**) Frequency histograms of food-seeking attempts of all animals during pre-CNO saline and CNO administration binned by the duration spent at the food chamber. p\>0.1, Kolmogorov-Smirnov test, comparing the distribution of durations during saline and CNO administration. N.S., not significant. Error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.009](10.7554/eLife.18716.009)10.7554/eLife.18716.010Figure 2---figure supplement 5.Administration of CNO (0.3 mg/kg) in control mice with mCherry-expressing ARC glia does not evoke increased food intake.(**A**) Design of the AAV construct expressing mCherry under the *Gfap* promoter. (**B**) Schematic of experimental paradigm. The mice were allowed to recover after surgery before being acclimatized to custom cages for three days (baseline) and to saline injection for three days (pre-CNO saline). CNO injections were repeated for three days, each separated by two days of saline injection (post-CNO saline) to allow the CNO effects to clear. All injections were performed at 09:00 while the food intake was measured at specific time points between 09:00--13:00. All mice were housed in custom cages between 09:00--13:00 and returned to the standard cages after 13:00 daily. (**C**) Total food intake between 09:00--13:00 during pre-CNO saline, CNO and post-CNO saline averaged across animals. p\>0.5, *n* = 7 animals, unpaired *t*-test comparing total food intake during three days of CNO administration with that during seven days of saline administration. (**D**) Food intake during hourly time points (except from 09:00--09:30 and 09:30--10:00 where 30 min time points were used) averaged across three days of pre-CNO saline and three days of CNO before taking the average across animals. *n* = 7 animals, ANOVA, Drug: p=0.701, F~(1,12)~ = 0.154; Time: p\<0.0001, F~(4,48)~ = 8.90; Interaction between drug and time: p=0.225, F~(4,48)~ = 1.47, comparing the population and trial averaged food intake at specific time points between 09:00--13:00 during pre-CNO saline and CNO administration. Food intake during 09:00--09:30 and 09:30--10:00 were normalized to hourly values. Two-way ANOVA followed by Bonferroni post hoc tests was used. N.S., not significant. Error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.010](10.7554/eLife.18716.010)10.7554/eLife.18716.011Figure 2---figure supplement 6.DREADD activation of glia does not lead to changes in body weight.(**A**) Averaged body weight across animals with (black, n = 5 animals) or without (grey, n = 8 animals) expression of hM3D(Gq)-mCherry in ARC glia. Injections of CNO or saline were performed once a day at 09:00 (ANOVA, Without and with expression: p\>0.9, F~(1,11)~ = 0.0160; Time: p\<0.0001, F~(12,132)~ = 18.2; Interaction: p\>0.8, F~(12,132)~ = 0.578, comparing the population averaged body weight without and with hM3D(Gq)-mCherry expression. Two-way ANOVA followed by Bonferroni post hoc tests was used. (**B**) Averaged body weight across animals with expression of hM3D(Gq)-mCherry in ARC glia. Injections of CNO or saline were performed twice a day at 09:00 and 17:00. *n* = 8 animals, p\>0.06, paired *t*-test comparing body weight measured during days of pre-CNO saline and CNO injections. N.S., not significant. Error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.011](10.7554/eLife.18716.011)

The CNO effect was also time-dependent when the population and trial-averaged food intake at specific time points between 09:00 and 17:00 during CNO and saline administration were examined. The time course revealed increased food intake within 30 min post CNO injection with peak feeding within 1 hr post injection. This effect persisted for at least 3 more hours ([Figure 2C](#fig2){ref-type="fig"}: *n* = 11 animals, two-way analysis of variance (ANOVA), Drug: p\<0.0001, F~(2,30)~ = 19.0; Time: p\<0.0001, F~(8,240)~ = 9.71; Interaction between drug and time: p\<0.0001, F~(16,240)~ = 11.6; see also [Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}). At peak feeding, the food intake was more than 13 times greater than that during saline administration ([Figure 2C](#fig2){ref-type="fig"}). It is worth mentioning that CNO administration evoked increased food intake within 3 hr post CNO application in the dark phase when majority of food intake occurs ([Figure 2---figure supplement 2A--C](#fig2s2){ref-type="fig"}). The total food intake in the 8 hr of dark phase was however not significantly different between CNO and saline application ([Figure 2---figure supplement 2D](#fig2s2){ref-type="fig"}). This may be due to a ceiling effect in the drive to feed when glia may already be activated at night (see section below).

We next compared the percentage of time viral-injected mice spent at the food chamber relative to other areas of the cage after CNO and saline administration ([Figure 2D](#fig2){ref-type="fig"}). The average percentage of time that mice spent at the food chamber following CNO administration was significantly greater than that following saline administration in the same mice ([Figure 2D](#fig2){ref-type="fig"}: *n* = 11 animals, ANOVA, Drug: p\<0.0001, F~(1,20)~ = 47.8; Time: p\<0.0001, F~(8,160)~ = 26.6; Interaction between drug and time: p\<0.0001, F~(8,160)~ = 22.7, comparing the population and trial-averaged time spent at food chamber at specific time points between 09:00 and 17:00 during pre-CNO saline and CNO administration). The same was true for the frequency of food seeking attempts ([Figure 2E:](#fig2){ref-type="fig"} *n* = 11 animals, ANOVA, Drug: p=0.003, F~(1,20)~ = 11.4; Time: p\<0.0001, F~(8,160)~ = 17.2; Interaction between drug and time: p\<0.0001, F~(8,160)~ = 10.1, comparing the population and trial-averaged frequency of attempts at specific time points between 09:00 and 17:00 during pre-CNO saline and CNO administration). CNO administration also increased the frequency of shorter-duration feeding attempts and increased the maximum duration of the feeding episodes ([Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}). Collectively, these observations suggest that glial activation can trigger mice to devote greater time for feeding.

A trend of increased CNO-induced food intake was observed with increased size of hM3D(Gq)-mCherry expression in the ARC ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). In mice lacking hM3D(Gq)-mCherry expression in ARC due to failed viral injection attempts (identified in post hoc analysis) ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}) as well as mice injected with the control virus AAV-*Gfap*-mCherry in ARC ([Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}), CNO administration did not increase food intake. Although glial activation resulted in the pronounced feeding response, DREADD activation of glia did not lead to changes in the body weight ([Figure 2---figure supplement 6](#fig2s6){ref-type="fig"}).

Collectively, these data support an active role of ARC glia in the modulation of feeding behavior and suggest that direct glial activation is sufficient to evoke acute feeding even during the daytime when the mice are normally resting and in calorically replete state.

Disruption of Ca^2+^ signaling pathway in ARC glia reduces food intake {#s2-3}
----------------------------------------------------------------------

The presence of activated ARC astrocytes during fasting ([Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}) suggests that glia may play a critical role in modulating feeding under physiological conditions. To address this question, we assessed the effect of reduced ARC glial activity on feeding by first injecting an AAV comprising a *Gfap* promoter-driven gene that encodes the pleckstrin homology (PH) domain of phospholipase C (PLC)-like protein p130 (p130PH) fused with mRFP (AAV-*Gfap*-p130PH-mRFP) in ARC. Glial expression of the p130PH construct was previously shown to disrupt the Ca^2+ ^ signaling in astrocytes *in vivo* by acting as a mobile cytosolic IP~3~ buffer to inhibit release of Ca^2+^ from internal stores ([@bib76]). Control animals were injected with AAV-*Gfap*-mRFP without the p130PH construct ([Figure 3A](#fig3){ref-type="fig"}). We compared the Fos activity of mRFP-expressing, S100B-positive ARC glia in the AAV-*Gfap*-p130PH-mRFP and AAV-*Gfap*-mRFP (control) injected animals after fasting. Indeed, the Fos activity of astrocytes in the AAV-*Gfap*-p130PH-mRFP injected animals was significantly lower than that in the control animals ([Figure 3B,C](#fig3){ref-type="fig"}: p130PH: *n* = 847 mRFP-expressing astrocytes, Control: *n* = 508 mRFP-expressing astrocytes, 8 animals each, p=0.0264, unpaired *t*-test, comparing averaged responses across astrocytes in each *Gfap*-p130PH-mRFP and control animal). The Fos activity of tanycytes, however, was not significantly different between the experimental and control groups ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). The Fos activity of neurons was significantly lower in experimental than in control animals ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}), suggesting possible glial-neuronal modulation (see below).10.7554/eLife.18716.012Figure 3.Disruption of Ca^2+^ signaling in ARC glia with selective expression of p130PH-mRFP leads to decreased Fos immunoreactivity.(**A**) Design of the AAV constructs expressing *Gfap* promoter-driven p130PH-mRFP and mRFP (control) respectively. (**B**) Fos immunoreactivity in mRFP-expressing (red), S100B-positive (green) ARC astrocytes is lower in fasted animals injected with AAV-*Gfap*-p130PH-mRFP than in control animals injected with AAV-*Gfap*-mRFP. Animals were perfused for Fos quantification 16--18 hr post initiation of fasting. Scale bar, 20 µm. (**C**) Population mean of normalized Fos expression in ARC astrocytes of AAV-*Gfap*-p130PH-mRFP and AAV-*Gfap*-mRFP injected animals. \*p\<0.05. Error bars represent SEM. See also [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.012](10.7554/eLife.18716.012)10.7554/eLife.18716.013Figure 3---figure supplement 1.Disruption of Ca^2+^ signaling in ARC glia with selective expression of p130PH-mRFP leads to decreased Fos immunoreactivity in neurons (but not in tanycytes) with no change in the body weight of fasted animals.(**A**) Fos immunoreactivity in mRFP-expressing tanycytes is not significantly different in fasted animals injected with AAV-*Gfap*-p130PH-mRFP than in control animals injected with AAV-*Gfap*-mRFP. Animals were perfused for Fos quantification 16--18 hr post initiation of fasting. Population mean of normalized Fos expression in ARC tanycytes of AAV-*Gfap*-p130PH-mRFP and AAV-*Gfap*-mRFP injected animals. p130PH: *n* = 22 tanycytes in 8 animals, Control: *n* = 24 tanycytes in 8 animals, p=0.651, unpaired *t*-test, comparing averaged responses across tanycytes in AAV-*Gfap*-p130PH-mRFP and AAV-*Gfap*-mRFP injected animals. (**B**) Fos immunoreactivity in non mRFP-expressing, S100B-negative ARC putative neurons is lower in fasted animals injected with AAV-*Gfap*-p130PH-mRFP than in control animals injected with AAV-*Gfap*-mRFP. Population mean of normalized Fos expression in ARC putative neurons of AAV-*Gfap*-p130PH-mRFP and AAV-*Gfap*-mRFP injected animals. p130PH: *n* = 718 putative neurons in 8 animals, Control: *n* = 600 putative neurons in 8 animals, p=0.0030, unpaired *t*-test, comparing averaged responses across putative neurons in AAV-*Gfap*-p130PH-mRFP and AAV-*Gfap*-mRFP injected animals. (**C**) Averaged body weight across AAV-*Gfap*-p130PH-mRFP (red, n = 8 animals) and AAV-*Gfap*-mRFP (blue, n = 8 animals) injected animals, measured after viral injection surgery. ANOVA, *Gfap*-p130PH-mRFP and *Gfap*-mRFP: p=0.805, F~(1,14)~ = 0.0630; Days: p\<0.0001, F~(17,238)~ = 32.6; Interaction: p=0.980, F~(17,238)~ = 0.420, comparing the population averaged body weight of AAV-*Gfap*-p130PH-mRFP and AAV-*Gfap*-mRFP injected animals. Two-way ANOVA followed by Bonferroni post hoc tests was used. \*\*p\<0.01, N.S., not significant. Error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.013](10.7554/eLife.18716.013)

We then compared the food intake of the *Gfap*-p130PH-mRFP-injected animals and control animals during both dark and light phases. Interestingly, the population and trial-averaged food intake was significantly lower in *Gfap*-p130PH-mRFP-injected animals than control animals in the dark phase but not light phase ([Figure 4A](#fig4){ref-type="fig"}: *n* = 8 animals, ANOVA, Drug: p\<0.0001, F~(1,14)~ = 30.3; Time: p\<0.0001, F~(19,266)~ = 72.9; Interaction between drug and time: p=0.0131, F~(19,266)~ = 1.92). This reduction of food intake during the dark phase was not compensated by an increase in food intake in the light phase as the cumulative food intake of *Gfap*-p130PH-mRFP-injected animals at the 24-hr time point (19:00) remained significantly lower than control animals ([Figure 4B](#fig4){ref-type="fig"}: *n* = 8 animals, ANOVA, Drug: p\<0.0001, F~(1,14)~ = 44.7; Time: p\<0.0001, F~(19,266)~ = 1091; Interaction between drug and time: p\<0.0001, F~(19,266)~ = 16.4). Similar to the DREADD experiments, no significant difference in the body weight was observed between *Gfap*-p130PH-mRFP-injected animals and control animals ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). Collectively, these findings support an essential role for glia in the modulation of feeding during physiological conditions.10.7554/eLife.18716.014Figure 4.Disruption of Ca^2+^ signaling in ARC glia with selective expression of p130PH-mRFP leads to decreased food intake in C57BL/6 mice during the dark phase.(**A**) Food intake during hourly time points (except from 19:00--19:30 and 19:30--20:00 where 30 min time points were used) in AAV-*Gfap*-p130PH-mRFP or AAV-*Gfap*-mRFP injected animals. Values between 19:00--19:30 and 19:30--20:00 were normalized to hourly values. (**B**) Cumulative food intake from 19:00--19:00 (24 hr, both dark and light phases) at the specific time points in AAV-*Gfap*-p130PH-mRFP or AAV-*Gfap*-mRFP injected animals. Values were averaged across three days of repeats before computing average across animals. Two-way ANOVA followed by Bonferroni post hoc tests was used. \*p\<0.05, \*\*\*p\<0.001, \*\*\*\*p\<0.0001. Error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.014](10.7554/eLife.18716.014)

Acute activation of glia facilitates the activity of AgRP/NPY neurons but not POMC neurons {#s2-4}
------------------------------------------------------------------------------------------

There is emerging evidence that astrocytes are integral components of brain circuits linked to specific brain functions and are capable of modulating neuronal responses ([@bib21]; [@bib31]). It is thus possible that the activation of DREADD-expressing glia can consequently modulate nearby ARC neurons to contribute to the observed evoked feeding behavior.

To test if this mechanism underlies the glial activation-induced increase in feeding, we investigated the potential role of the glial modulation of AgRP/NPY and POMC neurons. We first injected the hM3D(Gq)-mCherry virus in the ARC of *Npy*-hrGFP mice and *Pomc*-EGFP mice. Next, we performed *ex vivo* whole-cell current clamp recordings from NPY neurons (GFP-positive neurons in *Npy*-hrGFP mice) and POMC neurons (GFP-positive neurons in *Pomc*-EGFP mice) in brain slices containing hM3D(Gq)-mCherry-expressing ARC glia ([Figure 5A](#fig5){ref-type="fig"}). Interestingly, CNO activation of the hM3D(Gq)-mCherry-expressing ARC glia depolarized and/or increased the firing rate of AgRP/NPY neurons ([Figure 5B,C](#fig5){ref-type="fig"}: *n* = 15 neurons in 15 slices from 9 animals, p\<0.0001, unpaired *t*-test, comparing CNO-induced responses with null responses; averaged resting membrane potential: −52.2 ± 2.65 mV \[[@bib70]\]). In POMC neurons, CNO did not induce a significant response at a population level ([Figure 5B,C](#fig5){ref-type="fig"}: *n* = 14 neurons in 14 slices in 6 animals, p=0.370; unpaired *t*-test, comparing CNO-induced responses with null responses; averaged resting membrane potential: - 44.1 ± 2.09 mV \[[@bib18]\]). These findings were further validated by first injecting both *Npy*-hrGFP and *Pomc*-EGFP mice (with hM3D(Gq)-mCherry-expressing ARC glia) with either CNO or saline before performing Fos immunohistochemistry. Indeed, greater Fos immunoreactivity was observed after CNO injection as compared to saline injection in NPY but not POMC neurons ([Figure 5D--E,F](#fig5){ref-type="fig"}: *n* = 5 *Npy*-hrGFP animals each for CNO and saline injections, p=0.0428, unpaired *t*-test, comparing CNO and saline induced responses; *n* = 5 and n = 6 *Pomc*-EGFP animals for CNO and saline injections respectively, p=0.736, unpaired *t*-test, comparing CNO and saline induced responses). Collectively, these observations show that direct and acute activation of ARC glia facilitates the activity of AgRP/NPY but not POMC neurons.10.7554/eLife.18716.015Figure 5.CNO activation of hM3D(Gq)-expressing glia evokes facilitatory responses in NPY but not POMC neurons.(**A**) (**Top**) Configuration of whole-cell patch-clamp recordings of GFP-labeled NPY or POMC neurons in the ARC of coronal brain slices infected with AAV-*Gfap*-hM3D(Gq)-mCherry during CNO application. (**Bottom**) Merged green fluorescence (GFP), red fluorescence (mCherry) and differential interference contrast images of (**Left**) a GFP positive NPY neuron and (**Right**) a GFP positive POMC neuron patched in viral injected *Npy*-hrGFP and *Pomc*-EGFP slices respectively. Relative positions of (1) patch pipette and (2) CNO drug pipette were as indicated. Scale bars, 10 µm. (**B**) Local CNO application (red dot; 10 mM, 20 psi, 200 ms) evoked depolarizing response in (**Top**) an NPY (**Bottom**) but not in POMC neuron. (**C**) A population average of mean membrane potential (V~m~) of NPY or POMC neurons when CNO was applied. (**D**--**E**) *In vivo* injection of CNO induced greater Fos immunoreactivity in NPY neurons than saline injection. This was not observed in POMC neurons. Scale bars, 20 µm. (**F**) Population mean of normalized Fos expression in NPY and POMC neurons following saline or CNO injection. \*p\<0.05, \*\*\*\*p\<0.0001, N.S., not significant. Error bars represent SEM. See also [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}--[2](#fig5s2){ref-type="fig"}**DOI:** [http://dx.doi.org/10.7554/eLife.18716.015](10.7554/eLife.18716.015)10.7554/eLife.18716.016Figure 5---figure supplement 1.CNO does not evoke any response in NPY neurons when calcium is chelated in hM3D (Gq)-mCherry-expressing ARC astrocytes.(**A**) Electrophysiological characteristics of an astrocyte with the I-V curve showing absence of active membrane currents. (**B**) (**Left**) Spread of A633 (and BAPTA) in the syncytium within 30--45 mins of patching an astrocyte identified by its small round soma with thin radiating processes. Scale bar, 200 µm. (**Right Top**) NPY neurons were patched immediately after BAPTA/A633 dialysis within the hM3D(Gq)-mCherry-expressing astrocyte syncytium. (**Right Bottom**) Individual hM3D(Gq)-mCherry-expressing astrocytes were loaded with A633 (and BAPTA). Scale bar, 20 µm. (**C**) Local CNO application (red dot; 10 mM, 20 psi, 200 ms) did not evoke any response in NPY neurons after BAPTA/A633 dialysis of adjacent astrocytes through whole cell patch clamping of a passive astrocyte. (**D**) Population average of mean V~m~ of NPY neurons when CNO was applied in the absence and presence of BAPTA/A633 dialysis of adjacent astrocytes (p=1.18 E-5 and p=0.957, unpaired *t*-test, comparing CNO-induced responses with null responses in the absence and presence of BAPTA dialysis respectively). \*\*p\<0.01, \*\*\*\*p\<0.0001, N.S., not significant. Error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.016](10.7554/eLife.18716.016)10.7554/eLife.18716.017Figure 5---figure supplement 2.Administration of CNO (0.3 mg/kg) in Agrp-Ires-cre mice with hM4D(Gi)-mCherry-expressing AgRP neurons and hM3D(Gq)-mCherry-expressing ARC glia does not evoke any change in food intake.(**A**) Design of the 2 AAV constructs (1) AAV construct expressing hM3D(Gq)-mCherry under the *Gfap* promoter (2) AAV construct expressing hM4D(Gi)-mCherry using FLEX switch strategy to induce Cre-mediated transgene inversion and expression in AgRP neurons. (**B**) Expression of mCherry (red) co-localizes with anti-NeuN (blue, presumably AgRP/NPY neurons) and anti-S100B (green) immunohistochemistry. Scale bar, 10 µm. (**C**) Schematic of experimental paradigm. Mice were allowed to recover after surgery before being acclimatized to custom cages (baseline) and to saline injection for three days (pre-CNO saline). CNO injections were repeated for three days, each separated by a day of saline injection (post-CNO saline) to allow the CNO effects to clear. All injections were performed at 09:00 while the food intake was measured at specific time points between 09:00--15:00. (**D**) Total food intake between 09:00--15:00 during pre-CNO saline, CNO and post-CNO saline administration, averaged across animals. p\>0.2, *n* = 9 animals, unpaired *t*-test comparing total food intake during three days of CNO administration with that during five days of saline administration. (**E**) Food intake during hourly time points (except from 09:00--09:30 and 09:30--10:00 where 30 min time points were used) averaged across three days of pre-CNO saline and three days of CNO before taking the average across animals. *n* = 9 animals, ANOVA, Drug: p=0.684, F~(1,16)~ = 0.172; Time: p=0.0072, F~(6,96)~ = 3.15; Interaction between drug and time: p=0.520, F~(6,96)~ = 0.870, comparing the population and trial averaged food intake at specific time points between 09:00--15:00 during saline and CNO administration. Food intake during 09:00--09:30 and 09:30--10:00 were normalized to hourly values. Two-way ANOVA followed by Bonferroni post hoc tests was used. N.S., not significant. Error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.017](10.7554/eLife.18716.017)

To confirm that the CNO-evoked facilitatory responses in NPY neurons indeed have an astrocytic origin, we performed chelation of astrocytic Ca^2+^ by patch-clamping electrophysiologically characterized astrocytes ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}) with the cell-impermeable Ca^2+ ^ chelator 1,2-Bis(2-aminophenoxy) ethane-*N,N,N*′,*N*′-tetraacetic acid (BAPTA). The spread of BAPTA within the local syncytium of astrocytes through gap junctions ([@bib39]), visualized by including Alexa Fluor 633 (A633) in the patch pipette, was confirmed to be about 200 μm from the patched astrocyte after 20--50 min of dialysis ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Indeed, BAPTA chelation of Ca^2+^ in hM3D(Gq)-mCherry-expressing ARC astrocytes blocked the CNO-evoked depolarization in NPY neurons ([Figure 5---figure supplement 1C--D](#fig5s1){ref-type="fig"}: Control: *n* = 15 neurons in 15 slices in 9 animals, BAPTA: *n* = 5 neurons (patched after BAPTA dialysis of astrocyte syncytium) in 5 slices in 3 animals, p=0.0050, unpaired *t*-test, comparing responses in the absence and presence of BAPTA dialysis). Together these findings demonstrate that astrocytic Ca^2+^ activation contributes to NPY neuronal facilitation.

POMC neurons receive inhibitory inputs that mask the facilitation induced by ARC glial activation {#s2-5}
-------------------------------------------------------------------------------------------------

Although we have observed preferential activation of AgRP/NPY neurons over POMC neurons during ARC astrocytic activation, it is unclear how this cell-type specific modulation arises. Is this due to the intimate organization between astrocytes and specific neuronal subtypes? Or do astrocytes indiscriminately facilitate both AgRP/NPY and POMC neurons but their net responses shaped by the presence of a strong AgRP to POMC inhibition ([@bib9])? To dissect these possibilities, we first recorded spontaneous inhibitory postsynaptic currents (sIPSCs) from POMC neurons during CNO activation of hM3D(Gq)-mCherry-expressing ARC glia. Indeed, CNO evoked an increase in the frequency (but not amplitude) of sIPSCs in POMC neurons ([Figure 6A](#fig6){ref-type="fig"} *top*, 6B: *n* = 7 neurons in 7 slices in 3 animals, Amplitude: p=0.324; Frequency: p=0.0078, paired *t*-test, comparing normalized responses before and after CNO application). This observation reveals strong inhibition received by POMC neurons during glial activation, possibly via NPY neuronal activation. To test if facilitatory responses in POMC neurons evoked by glial activation can be unmasked when the strong inhibition they receive is blocked, we recorded the CNO-evoked responses in POMC neurons in the presence of GABA receptor (GABAR) blockers (50 μM Picrotoxin, a GABA~A~ receptor antagonist and 20 μM SCH-50911, a GABA~B~ receptor antagonist, see Materials and methods: Slice physiology). Interestingly, CNO evoked strong depolarization in POMC neurons when patched in the presence of GABAR blockers ([Figure 6A](#fig6){ref-type="fig"} *bottom*, [Figure 6C](#fig6){ref-type="fig"}: Control: *n* = 14 neurons in 14 slices in 6 animals, GABAR blockers: *n* = 7 neurons in 7 slices in 5 animals, p=0.0046, unpaired *t*-test, comparing responses between in the absence and presence of GABAR blockers). These data support our hypothesis that astrocytic activation facilitates both AgRP/NPY and POMC neurons indiscriminately. Unlike AgRP/NPY neurons, however, the presence of a strong inhibitory input, possibly due to the activation of AgRP/NPY-POMC inhibitory connection ([@bib9]) during glial activation, can further shape the net responses of POMC neurons. Our data thus suggest that ARC glial activation indiscriminately facilitates both AgRP/NPY neurons and POMC neurons but the presence of an inhibitory input leads to no net response in POMC neurons, thereby providing a mechanistic understanding of the glial activation-induced increase in feeding.10.7554/eLife.18716.018Figure 6.CNO activation of hM3D(Gq)-expressing glia evokes increased frequency of sIPSCs in POMC neurons.In the presence of GABAergic blockers, hM3D(Gq)-expressing glia activated depolarization in POMC neurons is revealed. (**A**) (*Top*) Local CNO application (red dot; 10 mM, 20 psi, 200 ms) evoked increased frequency of sIPSCs in POMC neurons patched in high chloride internal solution in the presence of bath application of NBQX. (**Bottom**) Local CNO application (red dot; 10 mM, 20 psi, 200 ms) evoked a facilitatory response in POMC neurons patched in the presence of picrotoxin and SCH-50911 (see Materials and methods: Slice physiology). (**B**) Population average of mean normalized amplitude and frequency of sIPSCs in POMC neurons before and after CNO application. (**C**) Population average of mean V~m~ of POMC neurons when CNO was applied in the absence and presence of GABAergic blockers (p=0.370 and p=0.0460; unpaired *t*-test, comparing CNO-induced responses with null responses). \*p\<0.05, \*\*p\<0.01, N.S., not significant. Error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.018](10.7554/eLife.18716.018)10.7554/eLife.18716.019Figure 6---figure supplement 1.Administration of CNO (0.3 mg/kg) in mice with hM4D(Gi)-mCherry-expressing ARC glia does not evoke any change in food intake.(**A**) Design of the AAV construct expressing hM4D(Gi)-mCherry under the *Gfap* promoter. (**B**) Schematic of experimental paradigm. Mice were allowed to recover after surgery before being acclimatized to custom cages (baseline) and to saline injection for three days. CNO injections were repeated for three days, each separated by two days of saline injection to allow the CNO effects to clear. All injections were performed at 19:00 while the food intake was measured at specific time points between 19:00--23:00. All mice were housed in custom cages between 19:00--23:00 and returned to the standard cages after 23:00 daily. (**C**) Total food intake between 19:00--23:00 during saline and CNO administration, averaged across animals. p\>0.2, *n* = 7 animals, unpaired *t*-test comparing total food intake during three days of CNO administration with that during seven days of saline administration. (**D**) Cumulative food intake from 19:00--23:00 at the specific time points, averaged across seven days of saline and three days of CNO administration before taking the average across animals. *n* = 7 animals, ANOVA, Drug: p=0.888, F~(1,12)~ = 0.0207; Time: p\<0.0001, F~(4,48)~ = 27.8; Interaction between drug and time: p=0.998, F~(4,48)~ = 0.0333, comparing the population and trial averaged cumulative food intake at specific time points between 19:00--23:00 during saline and CNO administration. (**E**) Food intake during hourly time points (except from 19:00--19:30 and 19:30--20:00 where 30 min time points were used) averaged across seven days of saline and three days of CNO before taking the average across animals. *n* = 7 animals, ANOVA, Drug: p=0.854, F~(1,12)~ = 0.0354; Time: p\<0.0001, F~(4,48)~ = 12.4; Interaction between drug and time: p=0.983, F~(4,48)~ = 0.0980, comparing the population and trial averaged food intake at specific time points between 19:00--23:00 during saline and CNO administration. Food intake during 19:00--19:30 and 19:30--20:00 were normalized to hourly values. Two-way ANOVA followed by Bonferroni post hoc tests was used. N.S., not significant. Error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.18716.019](10.7554/eLife.18716.019)

Acute activation of ARC glia while inactivating AgRP/NPY neurons does not increase food intake {#s2-6}
----------------------------------------------------------------------------------------------

To test if AgRP/NPY activation is necessary for glial activation-induced increase in feeding, we measured the food intake during simultaneous activation of ARC glia and inactivation of AgRP/NPY neurons. This was achieved by stereotaxic injection of both AAV-*Gfap*-hM3D(Gq)-mCherry and AAV-hSyn-DIO-hM4D(Gi)-mCherry in the ARC of Agrp-Ires-cre mice that allows selective expression of hM3D(Gq)-mCherry in ARC glia and hM4D(Gi)-mCherry in AgRP/NPY neurons ([Figure 5---figure supplement 2A--B](#fig5s2){ref-type="fig"}). The food intake of these viral-injected, *ad libitum* fed mice was then compared on days with CNO and saline injections ([Figure 5---figure supplement 2C](#fig5s2){ref-type="fig"}).

The average total food intake ([Figure 5---figure supplement 2D](#fig5s2){ref-type="fig"}) as well as population and trial-averaged time course of food intake ([Figure 5---figure supplement 2E](#fig5s2){ref-type="fig"}) during days of CNO administration were not significantly different from those during saline administration. This finding that AgRP/NPY activation is required to mediate the glial activation-induced increase in feeding further establishes the crucial role of the ARC glia-AgRP/NPY circuit in the regulation of energy balance.

Discussion {#s3}
==========

Our work shows that ARC glial activation enables increase in food intake via AgRP/NPY neurons. Interestingly, ARC glial activation facilitates both AgRP/NPY and POMC neurons. Unlike AgRP/NPY neurons, however, the responses in POMC neurons are further shaped by an inhibitory input, possibly due to activation of the AgRP/NPY neuron-POMC neuron inhibitory pathway ([@bib9]). The individual POMC neuronal responses are variable (see [Figure 5c](#fig5){ref-type="fig"}), suggesting varying relative strengths of the astrocyte-POMC and astrocyte-AgRP/NPY-POMC pathways. These competing pathways, however balance, revealing no significant response at the population level. Our findings show that although glial cells interact with distinct neuronal subtypes non-specifically, it can confer neuronal subtype-specific modulation through direct modulation of distinct neuronal circuits. This may be a common mechanism to explain the glial-neuronal subtype specific modulation observed in other brain regions ([@bib61]).

The lack of astrocyte-neuronal subtype wiring also suggests that glial activation may modulate other neuronal subtypes within the ARC. This thus opens the possibility of glial modulation of energy expenditure-promoting neurons in ARC e.g. GABAergic RIP-Cre neurons which do not overlap with the POMC and AgRP/NPY neuronal population ([@bib44]) and can potentially prevent the expected body weight gains during AgRP/NPY neuronal activation ([@bib45]). This may explain the absence of weight changes during ARC glial modulation observed in our study ([Figure 2---figure supplement 6](#fig2s6){ref-type="fig"}, [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}).

There are a few possible mechanisms that may underlie the non-specific, glial activation-stimulation of AgRP neurons and POMC neurons. These include: (1) astrocytic release of glutamate or D-serine gliotransmitters ([@bib29]; [@bib32]; [@bib59]; [@bib67]; [@bib71]); (2) regulation of extracellular transmitters ([@bib58]) or extracellular potassium ([@bib73]) possibly through changes in the activity of transporters in the astrocyte membrane ([@bib10]). Further investigation is required to dissect these possibilities.

Under physiological conditions, glial activation may occur via neuronal-glial interactions ([@bib5]; [@bib10]; [@bib22]; [@bib47]), possibly evoked by active AgRP/NPY neurons in the presence of a strong drive to feed ([@bib16]; [@bib50]). This, together with the strong glial-neuronal interactions observed in our work ([Figure 5A--C](#fig5){ref-type="fig"}, [Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}, [Figure 3B--C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}) suggest modulation of feeding by bidirectional communication ([@bib5]) between glia and neurons. Direct glial modulation by orexigenic molecules ([@bib52]) such as ghrelin via astrocytic ghrelin receptors ([@bib24]) may also be a possible mechanism to glial activation.

We manipulated glial Ca^2+^ activity bi-directionally with viral-mediated Gq-DREADD technology ([@bib1]; [@bib8]) and viral-mediated p130PH disruption of glial Ca^2+^ signaling ([@bib75], [@bib76]). Both methods allow local and specific manipulation of Ca^2+ ^signaling pathway of glia in ARC. The Gq-DREADD technology mimics acute activation of astrocytic GPCRs that triggers Ca^2+^ activation ([@bib1], [@bib2]) while the p130PH technology enables disruption of the endogenous PLC/IP~3~ glial Ca^2+^ signaling ([@bib49]; [@bib75], [@bib76]) during physiological feeding states. We have concerns using the Gi-DREADD technology to manipulate glial activity. Although the Gi-DREADD technology has been shown to inhibit neuronal firing via induction of hyperpolarization and inhibition of presynaptic neurotransmitter release ([@bib65]), it is unclear whether Gi-DREADD can affect glial activity or glial Ca^2+^ signaling pathways as these cells are electrically non-excitable and do not fire action potentials. In addition, existing work that activated Gi-coupled GPCR pathways in glia do not reveal any blockade of both astrocytic activity and astrocyte-neuronal modulation ([@bib3]). Indeed, we did not observe any effect of glial Gi-DREADD activation on feeding ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).

Previous work has provided evidence that support the role for astrocytes in feeding. This includes experiments showing chronic modification of feeding by synaptic remodeling ([@bib34]) during conditional deletion of astrocytic leptin receptors ([@bib41]) (see also [@bib37]) as well as observation of reactive gliosis ([@bib34]) and activation of astrocytic inflammatory signaling pathways after feeding of high fat diet ([@bib13]). These studies however do not address the question of whether direct glial-activation can evoke acute changes in feeding. The behavioral changes in feeding in these studies also cannot be solely isolated to the hypothalamus due to body-wide deletion of leptin receptors in GFAP-expressing cells (expression of GFAP ([@bib7]; [@bib14]; [@bib54]) and leptin receptors ([@bib11]; [@bib26]) occur in both the central nervous system and periphery). Our work directly addresses these gaps in knowledge by demonstrating a causal relationship between arcuate glia and acute as well as chronic modulation of food intake. We also further provide mechanistic evidence to explain how glial activation can differentially modulate AgRP/NPY and POMC neurons through direct modulation of distinct neuronal pathways and demonstrate the necessity of active AgRP/NPY neurons in mediating the glial activation-induced feeding.

A previous study ([@bib78]) investigating glial regulation of feeding by using the CNO-DREADD system reported distinct conclusions from our study. We attribute the differences to the use of different CNO doses and show that a high CNO dose (5 mg/kg) used in that study ([@bib78]) can in fact induce non-specific inhibition in feeding (see [Figure 2---figure supplement 1B--D](#fig2s1){ref-type="fig"}), possibly due to CNO-induced ataxia (Sigma-Aldrich's toxicological studies \[[@bib68]\]).

Our work, together with previous findings, collectively demonstrates a critical role of glia in the regulation of feeding and further establishes ARC as an important site of glial-mediated regulation. These findings also imply a possible causal link between increased ARC glial Ca^2+^ during astrogliosis ([@bib40]) and hyperphagia during ARC inflammation ([@bib20]). Future work in this area may reveal glia as a possible target of therapeutic intervention.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

All mice were housed at room temperature with a 12-hr light and 12-hr dark cycle (lights on: 07:00; lights off: 19:00). Mice were housed with cage mates except after surgery, during food behavior, Fos, glial morphological quantification and acute slice experiments where they were housed individually. For food behavior experiments, C57BL/6 (Taconic, Germantown, NY) and *Agrp*-Ires-cre (*Agrp*^tm1(cre)Lowl^/J; JAX 012899; Bradford B. Lowell, Harvard) adult mice of both gender, between 7--14 weeks old were used. For Fos experiments, acute slice whole cell patch-clamp, calcium imaging and immunohistochemistry experiments, C57BL/6, *Npy*-hrGFP ([@bib69]) (B6.FVB-Tg \[*Npy*-hrGFP\]1Lowl/J; JAX 006417; Bradford B. Lowell, Harvard), *Pomc*-EGFP ([@bib18]) (C57BL/6J-Tg(*Pomc*-EGFP)1Low/J; JAX 009593; Malcolm J. Low, University of Michigan Medical School) mice of both gender, between 7 weeks--8 months old were used. All mice were housed in standard cages except during behavior experiments where custom-designed cages with no bedding ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}) were used. Standard mouse chow in pellet form (Prolab RMH 3000, 5P00\*; Gross energy: 4.19 kcal/g, Metabolizable energy: 3.18 kcal/g, Physiological fuel value: 3.46 kcal/g; Protein: 25.999%, Fat: 14.276%, Carbohydrates: 59.725%) and water were provided *ad libitum.* All experiments were performed under protocols (0513-044-16) approved by the Animal Care and Use Committee at MIT and conformed to NIH guidelines.

Viral construct and injection {#s4-2}
-----------------------------

The AAV-*Gfap*-hM3D(Gq)-mCherry virus (Construct: Bryan Roth, UNC Chapel Hill, Addgene plasmid \# 50478; AAV Serotype 2/8, UNC Vector Core), AAV-*Gfap*104-mCherry virus (Construct: Ed Boyden, MIT, AAV Serotype 2/8, UNC Vector Core), AAV-*Gfap*-p130PH-mRFP and AAV-*Gfap*-mRFP viruses (Shinghua Ding ([@bib76]), Serotype 2/5), AAV-hSyn-DIO-hM4D(Gi)-mCherry virus (Construct: Bryan Roth, UNC Chapel Hill, Addgene plasmid \# 44362; AAV Serotype 2/8, UNC Vector Core) and AAV-*Gfap*-hM4D(Gi)-mCherry virus (Construct: Bryan Roth, UNC Chapel Hill, Addgene plasmid \# 50479; AAV Serotype 2/5, UNC Vector Core) were injected and specifically expressed in ARC glia. Mice were initially anesthetized with 4% isoflurane in oxygen and maintained on 1.5--2% isoflurane on a stereotaxic apparatus. The skull was exposed and a small hole was drilled above each side of ARC. Bilateral injection was performed with a glass micropipette (20--30 μm diameter) filled with 200 nl of virus at the following coordinates: bregma: AP:−1.40 mm, DV:−5.80 mm, L: ±0.30 mm. The injection speed was controlled at 100 nl/min with a micromanipulator (Quintessential Stereotaxic Injector, Stoelting). Mice were injected intraperitoneally with meloxicam (1 mg/kg) for postoperative care. Experiments were performed 2--3 weeks post-injection to allow for recovery and viral expression.

Food intake and feeding behavior studies {#s4-3}
----------------------------------------

*Ad libitum* fed mice were transferred from their standard cages to the open-top, custom-designed cages ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}) daily during the duration of the study. Each cage contained a food chamber, a drinking spout (water bottle external to the cage), mouse igloo and sterile gauze to substitute the removed bedding. The mouse igloo was positioned opposite to the food chamber in each cage and served to be an alternative location for rest and play. The weight of the food chamber was taken at specific time points using a weighing balance (CAS MWP-300N, 300 g, 0.01 g precision). In some experiments, measurements were taken after intraperitoneal injections of saline or clozapine-N-oxide (CNO, C0832, Sigma-Aldrich, St. Louis, MO) at 09:00 ([Figure 2B-E](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1E--F](#fig2s1){ref-type="fig"}, [Figure 2---figure supplements 4](#fig2s4){ref-type="fig"}--[5](#fig2s5){ref-type="fig"}, [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}), 19:00 ([Figure 2---figure supplement 1B--D](#fig2s1){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) or 22:00 ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). The feeding behavior was continuously recorded during the experiments with web cameras (Logitech, Newark, CA) positioned above the cages and the open source iSpy webcam software (iSpyConnect, Perth, Australia). Mice were transferred back to the standard cages after these experiments. CNO was administered at 0.30 mg/kg of body weight (see [Figure 2---figure supplement 1B--D](#fig2s1){ref-type="fig"}) while saline was given at the same volume as control.

Post behavior experiment localization of viral expression and immunohistochemistry {#s4-4}
----------------------------------------------------------------------------------

At the conclusion of the behavior study, all mice were perfused and the fixed brains were sectioned and imaged to confirm the stereotaxic accuracy of the viral injection site. Some of the sectioned slices were immunostained to verify the expression specificity of hM3D(Gq)-mCherry in glia. ***Perfusion***: Mice were anesthetized with 4% isoflurane and perfused transcardially with 0.1 M PBS followed by chilled 4% paraformaldehyde in 0.1 M PBS. The brains were then postfixed in 4% paraformaldehyde in 0.1 M PBS (\<4°C) overnight. Fixed brains were sectioned into 50--70 µm coronal slices (containing ARC) with a vibratome. ***Localization of viral expression***: The fixed slices were mounted on a glass slide with the Vectashield Hardset mounting media (Vector Labs, Burlingame, CA). The slides were imaged using a confocal microscope (Zeiss LSM 5 Pascal Exciter,Carl Zeiss, Oberkochen, Germany) and the images were analyzed for localization of mCherry ([Figures 1](#fig1){ref-type="fig"}--[2](#fig2){ref-type="fig"}, [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}) or mRFP ([Figures 3](#fig3){ref-type="fig"}--[4](#fig4){ref-type="fig"}) expression in ARC. ***Anti-*GFAP*/Anti-S100B and anti-NeuN immunohistochemistry***: The fixed slices were blocked in 10% normal goat serum with 0.5% triton in PBS (1 hr, room temperature) before being stained with mouse anti-GFAP (1:400,MAB360; Millipore, Billerica, MA) or mouse anti-S100B (1:600, S2532; Sigma) and rabbit anti-NeuN (1:250, ABN78; Millipore) in blocking buffer overnight (at 4°C). This was followed by a 3-hr incubation in Alexa Fluor 488 goat anti-mouse (1:200, Invitrogen, Carlsbad, CA, A11029) and Alexa Fluor 488 goat anti-rabbit (1:250, Invitrogen, A11034) in 1% normal goat serum and 0.3% triton, before being mounted on a glass slide with mounting media. Confocal imaging was performed and the images were analyzed for presence of co-localization of mCherry/mRFP and GFAP /S100B ([Figure 1C,E](#fig1){ref-type="fig"}, [Figure 3B](#fig3){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, [Figure 5---figure supplement 2B](#fig5s2){ref-type="fig"}), absence/presence of co-localization of mCherry and NeuN ([Figure 1D](#fig1){ref-type="fig"}, [Figure 5---figure supplement 2B](#fig5s2){ref-type="fig"}).

Anti-Fos immunohistochemistry and morphological analysis of glia {#s4-5}
----------------------------------------------------------------

Mice were perfused 2 hr post CNO/saline injection or 16--18 hr post initiation of fasting in fasted animals. The brains were post-fixed in paraformaldehyde over 2 nights before being sectioned into 100 µm coronal slices. The fixed slices were first incubated in 1.2% Triton-X-100 for 15 min before being blocked in 5% normal goat serum with 2% BSA and 0.2% Triton-X-100 in PBS (1 hr, room temperature). For anti-Fos immunohistochemistry, the slices were then incubated in blocking buffer containing rabbit anti-Fos (1:1000, PC38; Calbiochem, San Diego, CA) and in some experiments with mouse anti-S100B (1:600, S2532; Sigma) overnight at 4°C. For morphological analysis of glia, slices were incubated in blocking buffer containing rabbit anti-GFAP (1:400, G9269, Sigma) overnight at 4°C. This was followed by a 2-hr incubation in blocking buffer containing Alexa Fluor 647 goat anti-rabbit (1: 1000, Invitrogen, A21245) and Alexa Fluor 488 goat anti-mouse (in some anti-Fos immunohistochemistry experiments, 1:1000, Invitrogen, A11001) as well as 0.3 µM DAPI in PBS before being mounted on a glass slide with mounting media. Confocal imaging was performed with similar optical parameters for all slices imaged to ensure fair comparisons.

For anti-Fos immunohistochemistry experiment, MetaMorph Basic Offline (v. 7.7.0.0, Molecular Devices, Sunnyvale, California) was used for image quantification. Individual astrocytic glial cells were identified by the S100B and in some cases with mCherry/mRFP labeling ([Figure 1E-F](#fig1){ref-type="fig"}, [Figure 3B--C](#fig3){ref-type="fig"}, [Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}) while NPY/AgRP and POMC neurons were identified by their GFP expression ([Figure 5D-F](#fig5){ref-type="fig"}). In some cases, putative neurons were identified by DAPI and their lack of S100B and/or mRFP labeling ([Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"} and [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Tanycytic glial cells were identified by their location along the third ventricle next to the ARC ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}, [Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) and mCherry/mRFP labeling ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). These cells were then circled manually before the mean Fos signal for each cell was computed. Normalized Fos values were computed by normalizing raw Fos signal by the averaged Fos signal across control cells.

For morphological analysis of glia ([@bib63]), ARC glia with clear soma and processes were identified by GFAP labeling ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}, [Figure 1---figure supplement 1H](#fig1s1){ref-type="fig"}) and in some cases with mCherry expression ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Image stacks in 1 μm planes were then collected under 60x oil objective with 2x digital zoom. The glial cells were 10--90 μm from the surface. Image stacks were traced and 3D-reconstructed using the Neurolucida software (MBF Bioscience, Williston, VT). The coordinate files generated by the reconstruction were further analyzed by Sholl analysis using Neuroexplorer software (MBF Bioscience, Williston, VT). Virtual circles at increasing radii of 3.9 μm increments were drawn from the soma of each glia. The total length of GFAP-labeled processes passing through each circle and the number of intersections of processes with each circle were quantified ([Figure 1---figure supplement 1E--1F](#fig1s1){ref-type="fig"}, [Figure 1---figure supplement 1I--J](#fig1s1){ref-type="fig"})

Anti-vimentin immunohistochemistry {#s4-6}
----------------------------------

100 µm coronal fixed slices, prepared as described above, were stained with mouse monoclonal anti-vimentin (2 µg/ml, DSHB Hybridoma Product 40E-C, deposited to DSHB (Iowa City, Iowa) by Alvarez-Buylla, Arturo) followed by Alexa Fluor 488 goat anti-mouse (1:1000, Invitrogen, A11001).

Food intake and behavior analysis {#s4-7}
---------------------------------

The amount of food intake during a specific time segment for each mouse was computed by subtracting the weight of the food chamber at the beginning of the time point by that at the end of the time point. The time segment for total food intake was from 09:00--17:00 ([Figure 2B](#fig2){ref-type="fig"}, [Figure 2---figure supplement 4C](#fig2s4){ref-type="fig"}) or 09:00--13:00 ([Figure 2---figure supplement 5C](#fig2s5){ref-type="fig"}) or 09:00--15:00 ([Figure 5---figure supplement 2D](#fig5s2){ref-type="fig"}) or 19:00--23:00 ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}) or 22:00--06:00 ([Figure 2---figure supplement 2D](#fig2s2){ref-type="fig"}). The total food intake data was averaged across animals ([Figure 2B](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2D](#fig2s2){ref-type="fig"}, [Figure 2---figure supplement 4C](#fig2s4){ref-type="fig"}, [Figure 2---figure supplement 5C](#fig2s5){ref-type="fig"}, [Figure 5---figure supplement 2D](#fig5s2){ref-type="fig"}, [Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}) as well as averaged across trials and animals ([Figure 2C](#fig2){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}, [Figure 2---figure supplement 1C--E](#fig2s1){ref-type="fig"}, [Figure 2---figure supplement 2B--C](#fig2s2){ref-type="fig"}, [Figure 2---figure supplement 4D--E](#fig2s4){ref-type="fig"}, [Figure 2---figure supplement 5D](#fig2s5){ref-type="fig"}, [Figure 5---figure supplement 2E](#fig5s2){ref-type="fig"}, [Figure 6---figure supplement 1D--E](#fig6s1){ref-type="fig"}). Processing of the videos was done using in-house code written in MATLAB (Natick, MA). The average percentage of time spent at the food chamber was computed as (total time spent at the chamber in the time segment)/(total duration in the time segment)\*100% for each animal before taking the average across trials and animals ([Figure 2D](#fig2){ref-type="fig"}, [Figure 2---figure supplement 4F](#fig2s4){ref-type="fig"}). The average frequency of food-seeking attempts (/hr) was computed by counting the number of times each mouse approach (and stay) at the food chamber in the time segment before normalizing the count by the duration of the time segment considered before taking the average across trials and animals ([Figure 2E](#fig2){ref-type="fig"}, [Figure 2---figure supplement 4G](#fig2s4){ref-type="fig"}). The frequency-histogram was computed by binning the food-seeking attempts for all animals by the duration spent on the food chamber ([Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}, [Figure 2---figure supplement 4H](#fig2s4){ref-type="fig"}).

Slice physiology {#s4-8}
----------------

Coronal brain slices of ARC (300 µm) were prepared from AAV-*Gfap*-hM3D(Gq)-mCherry injected *Npy*-GFP and *Pomc*-EGFP mice with a vibratome (Leica VT 1200S, Leica, Wetzlar, Germany). Mice were anesthetized with Avertin solution (20 mg/ml, 0.5 mg/g body weight) and transcardially perfused with 15--20 ml of ice-cold carbongenated (comprising 95% O~2~/5% CO~2~, pH 7.33--7.38) cutting solution containing (in mM): 194 sucrose, 30 NaCl, 4.5 KCl, 1.2 NaH2PO4, 0.2 CaCl2, 8 MgCl2, 26 NaHCO3, and 10 D-(+)-glucose (360 mOsm). The slices were incubated in artificial cerebral spinal fluid (aCSF) at 32°C for 10 min followed by in fresh aCSF at room temperature for at least 1 hr. These slices were then transferred to a slice recording chamber for electrophysiology. The aCSF contained (in mM): 119 NaCl, 2.3 KCl, 1.0 NaH2PO4, 26.2 NaHCO3, 11 Glucose, 1.3 MgSO4, 2.5 CaCl2 (pH 7.4, 295--305 mOsm).

Whole-cell patch clamp recordings were performed with IR-DIC. All recordings were conducted at room temperature. The electrophysiological current-clamp recordings were filtered at 10 kHz and sampled at 10 kHz at gain = 1 while that for voltage-clamp recordings were filtered at 2 kHz and sampled at 10 kHz at gain = 5. The intracellular pipette solution for patching neurons in [Figure 5A--C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1C--D](#fig5s1){ref-type="fig"}, [Figure 6A](#fig6){ref-type="fig"} bottom, [Figure 6C](#fig6){ref-type="fig"} contained (in mM): 131 KGluconate, 17.5 KCl, 9 NaCl, 1 MgCl2.6H2O, 10 HEPES, 1.1 EGTA, 2 MgATP, 0.2 Na2GTP (pH 7.3, 300 mOsm). The intracellular pipette solution for patching astrocytes in [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"} contained (in mM): 50 KGluconate, 8 NaCl, 1 MgCl2, 10 HEPES, 13 K2SO4, 2 MgATP, 0.4 NaGTP, 40 BAPTA tetrapotassium salt (sc-202076, Santa Cruz Biotech, Texas, USA) (pH 7.3, 300 mOsm). Alexa Fluor 633 Hydrazide (A633, A30634, ThermoFisher Scientific, MA, USA) was also included to allow the observation of the spread of BAPTA in the astrocyte syncytium. The A633 was imaged with an orange-red excitation filter/far red emission filter. The intracellular pipette solution for patching neurons in [Figure 6A](#fig6){ref-type="fig"} top and [Figure 6B](#fig6){ref-type="fig"} contained (in mM): 103 CsCl, 12 Cs-methanesulfate, 5 TEA-Cl, 4 NaCl, 10 HEPES, 0.5 EGTA, 4 MgATP, 0.3 Na2GTP, 10 Phosphocreatine, 5 Lidocaine N-ethyl chloride (pH 7.4, 300 mOsm). Glass pipettes (3--5 MΩ, KG33, King Precision) were pulled with a Sutter P-97 puller (Sutter instruments). CNO (10 mM) was applied by pressure injection with a picospritzer (20 psi, 200 ms). In [Figure 6A](#fig6){ref-type="fig"} top, [Figure 6B](#fig6){ref-type="fig"}, 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo\[*f*\]quinoxaline-7-sulfonamide (10 µM NBQX, ab120045, Abcam, MA, USA) was bath-applied. In [Figure 6A](#fig6){ref-type="fig"} bottom, [Figure 6C](#fig6){ref-type="fig"}, picrotoxin (50 µM PTX, 1128, Tocris, Bristol, UK) was included in the intracellular pipette solution while SCH 50911 (20 µM, 9084, Tocris, Bristol, UK) was bath applied. In a select number of neurons, both PTX and SCH 50911 were included in the intracellular pipette solution and the data are also included in the population data in [Figure 6C](#fig6){ref-type="fig"}. GFP labeled NPY or POMC ARC neurons were visualized with an Olympus BX61WI microscope(Olympus, Tokyo, Japan) coupled with a 40x water immersion lens (Olympus). Recordings were performed with a multiclamp 700B amplifier and digidata 1440A data acquisition system, with pClamp software in the current-clamp mode. Analysis was performed with the Clampfit 10.2.0.12 software(Molecular Devices). The input resistances of the AgRP and POMC neurons patched in [Figures 5](#fig5){ref-type="fig"}--[6](#fig6){ref-type="fig"}, [Figure 5---figure supplement 1C--D](#fig5s1){ref-type="fig"} were comparable and agreed with previous literature ([@bib23]). The CNO-induced change in mean V~m~ in [Figures 5C](#fig5){ref-type="fig"}, [6C](#fig6){ref-type="fig"} and [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"} was defined as (Averaged membrane potential) ~after\ drug~ - (Averaged membrane potential) ~before\ drug~ where (Averaged membrane potential) was computed as the averaged membrane potential over 10 s. In [Figure 6B](#fig6){ref-type="fig"}, the amplitude and frequency of each event in the 120 s segment before and after CNO application was quantified before the population average was taken over all events in the respective segments. The population averaged amplitude or frequency of each segment was then normalized by the population averaged amplitude or frequency computed across events within the 120 s segment before CNO application.

Slice calcium imaging {#s4-9}
---------------------

Coronal brain slices of ARC (300 µm) were prepared from AAV-*Gfap*-hM3D(Gq)-mCherry injected C57BL/6 mice as described above. The slices were placed on a porous membrane in a 3.5 mm dish bathed in carbogenated aCSF. Oregon Green 488 BAPTA-1 AM (OGB) dye solution was prepared by adding 1 µl Pluronic F-127 (20% Solution in DMSO, P3000MP, ThermoFisher Scientific, MA, USA) and 49 µl DMSO to 50 µg of OGB (O6807, ThermoFisher Scientific). Bulk loading of the dye solution was performed by adding 3 µl of this dye solution over the ARC. After incubation at room temperature in the dark for 40 min, the slices were transferred to fresh aCSF for an additional 30 min before the experiment.

hM3D(Gq)-mCherry glia in ARC were visualized with an Olympus BX61WI upright microscope under a 40x/0.80 W Olympus LUMPlanFL N water immersion lens and an Olympus CellSens dimension (v 1.6)-driven Hamamatsu ORCA-R2 digital CCD camera (C10600). Fluorescence was continuously excited using a Lumen 200/220 (Prior Scientific, MA, USA). OGB1-AM and mCherry were imaged with a blue excitation filter/green emission filter and a green excitation filter/red emission filter, respectively. Images were continuously acquired at 1.25 Hz, using 1x1 binning. Images were saved by the CellSens software as tagged image fileformat files and analyzed with both ImageJ (NIH) and custom-written MATLAB scripts. Individual cells were circled manually based on the mCherry expression. The mean fluorescence for each cell was computed from frame to frame, giving a time-varying intensity signal for each cell. After correction for lamp flicker noise and dye photobleaching, dFF was calculated by subtracting the local corresponding baseline (F) from the peak of the response to get dF before taking the ratio by F. Increases in dFF in ROIs indicated an increase in Ca^2+^ concentration.

Statistics {#s4-10}
----------

Analysis was performed using GraphPad Prism (La Jolla, CA). Two-way ANOVA followed by Bonferroni post hoc tests and standard two-tailed paired or unpaired *t*-test were used as indicated in text. A p value of less than 0.05 was considered significant in these studies. Error bars indicate S.E.M. Blind experiments were performed for the Fos and slice physiology studies. Blind experiments were not performed for the behavior studies but the same criteria were applied to all allocated groups for comparisons. No randomization was performed for the study. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported to previous publications ([@bib18]; [@bib45]; [@bib74]).
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Palmiter

Richard D

Reviewing editor

Howard Hughes Medical Institute, University of Washington

,

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Direct modulation of GFAP-expressing glia in the arcuate nucleus bi-directionally regulates feeding\" for consideration by *eLife*. Your article has been favorably evaluated by a Senior Editor and three reviewers, one of whom, Richard D Palmiter (Reviewer \#1), is a member of our Board of Reviewing Editors. The following individual involved in review of your submission has agreed to reveal their identity: Michael Krashes (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

This paper demonstrates quite convincingly that activation of arcuate astrocytes using DREADD technology can stimulate daytime feeding, while inhibition of arcuate astrocytes inhibits nighttime feeding. Furthermore, the authors provide evidence that this phenomenon is likely mediated by astrocyte activation of AGRP neurons. This is the first paper to show that astrocytes are important players in regulation of food consumption, and may explain (in part) why inflammation caused by consumption of a high-fat diet promotes weight gain if the inflammatory signals were to chronically activate astrocytes.

Below is a list of recommendations (summarized from the three reviews) that the authors should address in their revised manuscript and response.

1\) The arcuate is a fairly large structure and it can be difficult to manipulate; hence, the extent of viral transduction of glia in the arcuate should be assessed. Ideally, the extent of transduction for each mouse could be correlated with the effect on appetite.

2\) Glia change shape with activation. Did that occur with hM3Di activation? Are astrocytes activated to the same extent by fasting as observed with hM3Dq and CNO?

3\) The loss of function studies are critical for knowing whether glia are important players in regulation of food intake. There is concern (especially in view of a previous paper by Yang et al) regarding the method used to study the effect of glia inactivation. Inclusion of studies using an inhibitory DREADD, hM4Di, at the same low dose of CNO used for the activation studies would be appropriate; alternatively explain why they were not chosen. An advantage of chronic inhibition of glia with the p130PH-mRFP method is that the long-term effect on body weight could be assessed? Those data should be included. Does chronic activation of glia affect body weight?

4\) The authors provide Fos and EPhys evidence that AgRP neurons are preferentially activated in response to glial activation. Is the AgRP activation responsible for the increase in food consumption? Activating the glia while inactivating AgRP neurons would provide a definitive answer to this question. Alternatively, the authors should indicate that AgRP neuron activation is just one plausible mechanism.

5\) The potential mechanism by which glial activation stimulates AgRP neurons should be discussed in more depth.

More specific comments from the reviewers that add depth to the requests above are indicated below. These comments do not require individual responses.

1\) The authors state that they are selectively manipulating GFAP-expressing glia of the ARC, however this is loosely defined. The ARC is a fairly long structure spanning almost 1 mm both rostral to caudal and medial to lateral. It would be insightful if the authors made some sort of schematic to display the expression of the hM3D(Gq) virus. I imagine glia are present throughout the ARC and importantly throughout the entire hypothalamus. How certain are the authors that DREADD expression was specific for the ARC? Additional images would help convince the reader that they are selectively manipulating their intended targets. This becomes particularly critical when comparing the results here to the previous findings of Yang et al., 2015 whereby GFAP- hM3D(Gq) was expressed throughout the medialbasal hypothalamus.

2\) It should be noted that the cumulative food intake reported from 9:30-17:00 is extremely low (on average of 0.1 grams; [Figure 2B](#fig2){ref-type="fig"}). Although the light cycle is normally a time for calorically replete mice to rest, most reports observe feeding behavior during this time of about 10-20% of an animal\'s daily food intake. An explanation for this discrepancy could be the custom-designed cages versus home cage which could induce additional stressors on the animals even following the acclimation period. This very low baseline makes the CNO versus saline GFAP- hM3D(Gq) effects appear disproportionately large. Again, this could be due to the specific behavioral setup but perhaps home cage assessment of food intake may strengthen this claim.

3\) It is unclear why the authors chose to use p130PH-mRFP as a method to disrupt ARC glia signaling as opposed to hM4D(Gi), the latter of which is reversible and far more acute. This tool has been used previously. Also, further characterization of the Gfap-p130PH-mRFP mice should be reported. For example, it is quite remarkable that these mice show such a sharp reduction in cumulative food intake; does this result in a leaner phenotype over an extended period of time? How does this compare to other manipulations that result in a drastic decrease in feeding behavior?

4\) A proposed mechanism of AgRP/NPY, and for that matter POMC, neurons are described here. It may be worth discussing a possible glutamate-release mechanism accounting for this activation as previously described in GFAP- hM3D(Gq)-expressing glia in Scofield et al., 2015. It would also be worth discussing how a proposed glutamate release into extracellular space could be specific for certain cell-types.

5\) When differentiating between the present study and that of Yang et al., 2015, the authors propose that the high CNO dose (5 mg/kg) can induce non-specific inhibition of feeding, which they show here (although baseline seems to be higher here in saline injected mice). However, although this would explain the reduction of feeding observed in the Yang et al., 2015 paper using GFAP- hM3D(Gq), it contradicts the GFAP-hM4D(Gi) elevated ghrelin-evoked feeding and blunted leptin-induced anorexia (both net gains of food intake) observed previously. Again, I think the major reason for these differences seen between these two studies is the expression of the GFAP-DREADDs, which should be more focused here.

6\) This could also at least start to explain the electrophysiological differences between these two studies in which AgRP/NPY neurons are activated (here) or inhibited (Yang et al., 2015). The authors show a sample trace of CNO-induced increased frequency of AgRP/NPY neurons but should quantify this.

7\) It is important to show the regulation of activities differentially in NPY/AGRP and POMC neurons by glia in the ARC and the physiological outcomes of this pathway in whole animals. However, it is not clear whether this pathway really participates in the development of obesity (body weight gain) or eating disorders (loss of body weight) in animals, which lessens the impact of this study.

8\) It was not clear how glial cells activated NPY/AgRP cells and how glial activation was modulated by cues encoding the energy status of animals in this study. Without the understanding of these questions in this manuscript, the study is mostly descriptive, and potentially, reports on artifact.

9\) To establish the effect of glial activation of NPY/AgRP neurons on the regulation of feeding, the authors should also demonstrate that silencing NPY/AgRP cells with an inhibitory DREADD receptor is able to eliminate the effect of glial activation with the stimulatory DREADD receptor expressed in glia on feeding.

10\) To verify the results obtained in this report with a stimulatory DREADD receptor, the authors should use an inhibitory DREADD receptor to show opposite effects in mice.

11\) It is known that in different energetic states (HFD, fasting) astrocytes change their morphology. In the present paper the authors investigated the role of astrocyte activation in AgRP and POMC neurons, but they obviated the effects that astrocyte activation has on the astrocytes themselves. Morphology studies on astrocytes should be carried (at least length and number of ramifications).

12\) The authors compared acute activation with a fasting state. First, they don´t provide astrocyte activation after fasting. This must be measured. Then, they link the glia-neuron interaction to the calcium signaling in astrocytes. When calcium signaling in the astrocytes of the Arc is disrupted, the acute activation doesn´t have any feeding effect. If the authors said the activation has the same effects as fasting, they need to provide that fasting modulates calcium signaling in the astrocytes of the ARC. They also need to show that acute activation increases calcium signaling.

13\) In order to show that astrocyte activation affects AgRP and POMC, they checked the activation measuring FOS and performing e-phys studies. In AgRP, they found increased firing, and in POMC no changes in firing, but differences in inhibitory events (maybe coming from the AgRP/NPY cells). They need to provide data of excitatory and inhibitory events onto NPY cells after CNO administration.

14\) They conclude that direct modulation of astrocytes regulates feeding, but they only describe effects when they \"activate\" astrocytes. What is it happening when astrocytes are inactivated? Can the acute inactivation abolish feeding response to fasting? Can the acute or systemic inactivation of astrocytes impair the morphological changes triggered by fasting?
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Author response

Below is a list of recommendations (summarized from the three reviews) that the authors should address in their revised manuscript and response.

*1) The arcuate is a fairly large structure and it can be difficult to manipulate; hence, the extent of viral transduction of glia in the arcuate should be assessed. Ideally, the extent of transduction for each mouse could be correlated with the effect on appetite.*

We have quantified the extent of viral transduction of glia in the arcuate and confirmed that the CNO-induced feeding increased with increased size of viral transduction ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}).

*2) Glia change shape with activation. Did that occur with hM3Di activation? Are astrocytes activated to the same extent by fasting as observed with hM3Dq and CNO?*

We have observed a greater complexity of astrocytic processes in hM3D(Gq)-mCherry expressing arcuate glia of CNO-injected animals than in control animals injected with saline ([Figure 1---figure supplement 1D-F](#fig1s1){ref-type="fig"}).

We have also observed a greater complexity of astrocytic processes in arcuate glia of fasted animals than in control fed animals ([Figure 1---figure supplement 1H-J](#fig1s1){ref-type="fig"}).

Both the morphology studies ([Figure 1--- figure supplement 1D-F](#fig1s1){ref-type="fig"} and [Figure 1---figure supplement 1H-J](#fig1s1){ref-type="fig"}) and FOS immunoreactivity study ([Figures 1F](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}) suggest that activation of hM3D(Gq)-mCherry in astrocytes can induce both functional and morphological changes observed during physiological activation of astrocytes after fasting.

*3) The loss of function studies are critical for knowing whether glia are important players in regulation of food intake. There is concern (especially in view of a previous paper by Yang et al) regarding the method used to study the effect of glia inactivation. Inclusion of studies using an inhibitory DREADD, hM4Di, at the same low dose of CNO used for the activation studies would be appropriate; alternatively explain why they were not chosen.*

We performed the suggested experiment and did not observe any significant difference in the dark phase feeding after saline and CNO (0.3 mg/kg) injection in animals with hM4D (Gi)-expressing arcuate glia ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).

We have concerns with the hM4D(Gi) method because it is not known whether activating hM4D(Gi) affects astrocytic activity. In neurons, hM4D(Gi) inhibits firing via induction of hyperpolarization by Gβ/γ-mediated activation of G-protein inwardly rectifying potassium channels and inhibition of presynaptic neurotransmitters release (Roth, Neuron, 2016). The mechanisms of hM4D(Gi) activation in glia or astrocytes however remain largely unknown, as these cells are electrically non-excitable and do not fire action potentials. In addition, there is no literature that has demonstrated the effects of hM4Di activation on inactivating glial calcium pathway. Existing work that activated Gi-coupled GPCR pathways in glia also do not reveal any blockade of both astrocytic activity and astrocyte-neuronal modulation (Agulhon et al., 2012).

The p130PH-mRFP approach was chosen as it has been previously demonstrated to disrupt the PLC/IP~3~ calcium signaling in astrocytes in vivo (Xie et al., Neuroscience, 2010). In addition, we have also observed that the Fos activity is lower in p130PH-mRFP expressing glia than in control glia after fasting ([Figure 3B-C](#fig3){ref-type="fig"}).

We have improved our discussion to explain the choice of method for glia 'inactivation': "We manipulated glial Ca^2+^ bi-directionally \[...\] did not observe any effect of glial Gi-DREADD activation on feeding".

*An advantage of chronic inhibition of glia with the p130PH-mRFP method is that the long-term effect on body weight could be assessed? Those data should be included. Does chronic activation of glia affect body weight?*

We observed no significant difference in the body weight of AAV-*Gfap*-p130PH-mRFP- and AAV-*Gfap*-mRFP-injected mice up to 11 weeks post injection ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}).

Glial activation may modulate other neuronal subtypes within the ARC, which in turn trigger diverse physiological functions. Besides its effect on feeding, ARC glia may also regulate energy expenditure. Regulation of energy expenditure via glia may be mediated through GABAergic RIP-Cre neurons that also exist in the ARC and are well known as regulators of energy balance (D. Kong et al., Cell, 2012). The simultaneous regulation of feeding and energy expenditure by glia may account for the lack of change in body weight in the Gq-DREADD experiments ([Figure 2---figure supplement 6](#fig2s6){ref-type="fig"}) and p130PH experiments ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}).

We have provided a brief discussion: "The lack of specific astrocyte-neuronal subtype wiring \[...\] glial modulation observed in our study."

*4) The authors provide Fos and EPhys evidence that AgRP neurons are preferentially activated in response to glial activation. Is the AgRP activation responsible for the increase in food consumption? Activating the glia while inactivating AgRP neurons would provide a definitive answer to this question. Alternatively, the authors should indicate that AgRP neuron activation is just one plausible mechanism.*

We performed this experiment and observed that astrocytic activation by CNO (as compared to control when saline was injected) did not evoke any change in food intake when AgRP/NPY neurons were inactivated in Agrp-Ires-cre mice with hM4D(Gi)-expressing AgRP neurons and hM3D(Gq)-mCherry expressing arcuate glia ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). This supports the hypothesis that AgRP neuronal activation is necessary for glial activation-induced increase in feeding.

*5) The potential mechanism by which glial activation stimulates AgRP neurons should be discussed in more depth.*

We have included a Discussion paragraph to address this: "There are a few possible mechanisms \[...\] Future investigation is required to dissect these possibilities."

*More specific comments from the reviewers that add depth to the requests above are indicated below. These comments do not require individual responses.*

We thank the reviewers for their specific comments. We have made the suggested language changes.

[^1]: These authors contributed equally to this work.

[^2]: These authors also contributed equally to this work.
